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Abstract
Blood transfusion is a well-accepted medical technology that cur-
rently relies on a supply of red blood cells from many thousands of altruistic donors.
Cultured red blood cells using stem cell technology could offer a replacement technology,
providing a limitless supply of red blood cells from a single source. This project used
interviews and focus groups to explore the views of a wide range of publics towards
cultured red blood cells. This paper explores how participants referred to a lack of
biodiversity in cultured red blood cells in three ways. The first was as a comparison
to GM crops, with concern over a monopoly on blood supplies. The second was a
perceived increased risk associated with a single source of blood. Thirdly participants
saw the lack of biodiversity as a threat to the altruistic nature of blood donation from
multiple donors.
Introduction
This paper is about a research project which looked at the
views of various publics towards the use of stem-cell-derived red blood cells for
transfusion. During the course of the research it was found that many partici-
pants compared this new technology with that of genetically modified (GM)
crops. In this paper I discuss how, in interviews and focus groups, GM crops
were used to describe a perceived lack of biodiversity. I introduce the transition
to cultured red blood cells as a continuation of historical aspects of blood
donation, to show the transition from donor gift to potential laboratory project.
I will also look at the attitudes towards GM crops in the UK, to discuss how a
perceived lack of biodiversity and the ‘scientification’ of nature are regarded as
inherently more risky.
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The historical context of donor blood transfusion
Although bloodletting was first recorded in 430BC and re-
mained a common practice until the nineteenth century,1 blood transfusion is
a relatively recent clinical practice. In 1628 Harvey’s2 book provided the know-
ledge needed for early animal transfusion experiments by Lower in 1665 and
Cox in 1666-67.3 The recognition of the need to transfuse humans only with
human blood 1818 was made by James Blundell, with blood types identified by
Karl Landsteiner in 1901.4 Routine blood typing was not practised until the
1920s, with the rhesus positive and negative blood types identified in 1941.5
Percy Oliver’s list of blood donors was started in 19216 but it was not until 1937
that Bernard Fantus set up the blood bank as we now know it, with blood re-
frigerated for up to ten days. Today blood is one of medicines’ ‘most vital com-
modities’7 and the UK alone transfuses 2.2 million units of blood each year.
Donation and transfusion is overseen by the NHS, with four transplant services
covering England and North Wales, South Wales, Northern Ireland, and Scot-
land. The Scottish National Blood Transfusion Service (SNBTS) is the main
focus of the research reported in this paper.
The need for a new method of transfusion
TheUKhas an established and effective blood donation system
but there are challenges which highlight the need for alternative methods of
blood transfusion. Preventing contamination of donated blood with transfusion
transmitted infections (TTIs) requires large amounts of blood testing, bringing
with it associated rises in cost.8 Acquiring adequate donors is another major
hurdle, with donor numbers falling and the UK transfusion services heading
towards a recruitment crisis. Currently only 4% of the UK population are re-
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gistered blood donors,9 and the Scottish National Blood Transfusion Service
expressed a need to raise the donor levels from 175,000 in 2008 to 210,000 in
2010.10 Many innovations have been proposed to overcome the dual challenges
of donor recruitment and possible infection risk. Haemoglobin-based oxygen
carriers (HBOCs),11 derived from human or animal blood and Perfluorocarbons
(PFCs),12 which are synthetic oxygen carriers, were heralded as an alternative
to red blood cell transfusion. Unfortunately neither product performed well in
clinical trials and are not licensed for use in the UK or USA.13, 14
This paper concerns the Novosang product, which is another proposed
technology to overcome both the requirement for donors and the infection risk.
Rather than using chemical substitutes for blood, the project goal is to culture
red blood cells in the laboratory, providing a limitless and infection free source
of blood for transfusion. To date the project has received over £ 12 million in
funding from organisations including theWellcome Trust, the Scottish Funding
Council, Scottish Enterprise, the Scottish National Blood Transfusion Service
and NHS Blood and Transplant.15 By the time the project finishes it is hoped
that it will generate small quantities of blood suitable for initial animal and
human safety tests.
The reaction of the wider public to this novel method of producing red blood
cells was unknown. Blood donations in the UK come from altruistic donors,
which has impacted on the interesting ‘gift relationship’ view of blood transfu-
sions, as was portrayed in Titmuss’16 book of the same name. Studies have
shown that donated blood is still preferable to other forms of blood replacement.
Ferguson et al.17 found that the public viewed blood substitutes as a ‘substandard
replacement’ for actual blood, an unnatural and synthetic alternative. A study
carried out by Fleming et al.18 found that those studied had a preference for
donor blood, being regarded as the most effective, most ethically acceptable
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and least ‘risky’. This was followed by chemical-based substitutes, bacteria-
grown substitutes and finally bovine-derived substitutes, which were seen as
being the most risky, least ethically acceptable and least effective. Notably, per-
ceptions of risk correlated with both ethicality and effectiveness for all of the
options. The Fleming study shows that human donor blood was still seen as
the preferred option by those who were interviewed. Other research on blood
and blood substitutes has identified a greater acceptability of blood substitutes
amongstmedical professionals, when compared to journalists or blood donors.19
There was also a marked difference between the risk levels perceived by these
groups concerning the infection rates through donation. However, none of
these papers looked at cultured red blood cells using stem cell technology, and
Ferguson et al. argued that a more effective ‘marketing’ of alternative blood
products may change the views that their respondents had expressed. Previous
developments in the blood products industry, such as the use of recombinant
DNA technology to provide Factor VIII, show that it is possible for an alternative
technology to become assimilated into mainstream practice.
This project set out to discover the reactions of various publics in Scotland
towards cultured red blood cells. In this paper I report specifically on the theme
of biodiversity as it was used by our participants in interviews and focus groups,
and particularly as it was used in comparison to GM crops. Given the focus of
this paper it is necessary to understand how such crops are viewed in the context
of the UK, where this research was conducted.
GM crops in the UK
GM crops in the UK (and in the rest of Europe) have not been
publicly accepted in the way that such crops have been in areas such as North
America and China.20 Since 2001 only one GM crop has been approved for
cultivation in Europe.21 Images of protesters in biohazard suits destroying fields
of GM crop tests were widely portrayed in the UKmedia during the late 1990s.
The website www.genewatch.co.uk states that currently no commercial GM
crops are grown in the UK although testing of such crops does continue. GM
products enter the UK from abroad in food, animal feed, and biofuels. At the
K.C. Lowe, K. Farrell, E.M. Ferguson & V. James, ‘Current perceived risks of transfusion in
the UK and relevance to the future acceptance of blood substitutes’, Artificial Cells, Blood Sub-
stitutes, And Immobilization Biotechnology 29:3 (2001), 179-189.
19
D. Burke, ‘GM food and crops: what went wrong in the UK? Many of the public's concerns
have little to do with science’, EMBO Reports 5:5 (2004), 432-436.
20
Y. Devos, O. Sanvido, J. Tait & A. Raybould, ‘Towards a more open debate about values in de-
cision-making on agricultural biotechnology’, Transgenic Res. 23:6 (2014), 933-943.
21
Journal of Medical Law and Ethics 2015-3154
KING
time of writing this paper (August 2015) debates have once again resurfaced in
the media after Scotland declared a ban on the growing of GM crops.
Fears about GM crops in the UK have stemmed from a perception that
transgenes used in GM crops could transfer into other wild plants or non-GM
crop species.22 There has also been a backlash onmoral principles towards large
commercial companies having control over crop production. Terminator tech-
nology, which prevents farmers from storing seed for planting the following
year, means that growers must return to the GM company and rebuy seed each
year. Some consider this to be locking farmers into a continuing relationship
with the commercial company, whilst others see this as the only way to prevent
crops spreading in the wild and for companies to guarantee a return on their
investment. Some argue that basing a risk assessment of GM crops on public
attitudes has distanced the argument from scientific facts, pointing out that
many of these risk factors have been founded on human emotions and not on
scientific data.23
Methods
As part of our research into this new method of producing
blood, focus groups and interviews were carried out with a variety of publics.
The research methods used for this project will be described in more detail
elsewhere.
Four key groups were targeted:
– Patients who undergo regular blood transfusions, for example for sickle
cell disease or thalassaemia.
– Representatives of religious or moral groups who could contribute to the
discussion on cultured red blood cells from an ethical or religious stand-
point.
– Clinical groups, such as doctors and nurses, who use blood transfusions
in the course of their work.
– Community groups chosen to represent a spread of publics, who may not
have a background in science or medicine. These included sports clubs,
arts groups, etc.
Interviews were conducted with those who it were felt were ‘experts’ in their
field – which included doctors, ethicists, members of religious organisations,
A.F. Raybould & A.J. Gray, ‘Will hybrids of genetically modified crops invade natural commu-
nities?’, Trends in Ecology & Evolution 9:3 (1994), 85-89.
22
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and patients. Focus groups were used to bring together those who might not
have previously considered the issues involved in cultured red blood cells, and
included community and sports groups, a college group, and residents in a
residential care home for the elderly. The majority of data collection took place
in Scotland, apart from a focus group with one patient group which took place
in London, and one expert interview in northern England. In total there were
27 data collection sessions, including interviews, full focus groups (approx. two
hours) and mini focus groups (which ran from a few minutes to one hour and
were often unrecorded). The interviews and focus groups which had been voice
recorded were transcribed verbatim and then the transcripts and notes from
unrecorded sessions were coded using NVivo software. A grounded theory
methodology24was used, to draw information from the data rather than starting
with preconceived theories. In total 22 nodes were used, of which one of these
described the views of the interviewees towards the ‘biodiversity’ of the cultured
blood product.
Results
The theme of biodiversity was discussed by our respondents
in a number of ways. These included feelings of ‘everything being the same’,
and of cultured blood production being like ‘GM crops’. These conversations
around biodiversity are divided into three interlocking themes of commercial-
isation, risk associated with a lack of biodiversity, and social considerations.
Theme 1: Commercialisation
The first theme saw participants compare cultured red blood cells to the
perceived commercialisation of GM crops. Participants reflected on the way
that a ‘free’ product was being turned into a profit making facility – both in the
commercialisation of crops which would grow naturally and in the commercial-
isation of blood which is currently obtained from altruistic donors. This of
course glosses over many of the current production costs necessary in both
farming and blood transfusion. With increased commercialisation came an
appreciation of the rising power wielded by those in control of the product.
‘And my sinister side would say, is there any way that a large corporation could
say “and you now need to come back to us” and there would be some kind of power
base. Like the genetically modified crop companies in the US who have made it so
that any farmer now wanting to farm for the major supermarket chains will then
A.L. Strauss & J. Corbin, ‘Grounded Theory Methodology’, in: N.K. Denzin & Y.S. Lincoln
(eds.),Handbook of Qualitative Research (Sage, 1994).
24
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harvest the grain and will need to go back to the GM company because it only has a
rate of regeneration for one year only. And you are then going cap in hand again to
buy more seed. And they have deliberately done that in their economic engine of “and
you will need us”.’ (Interview)
Participants raised concerns that the use of blood would be restricted to
those who could afford to pay for it, and that the supply of blood might be tied
to a particular commercial company who had control over the use of blood by
health-care systems. There was also a feeling of unease that commercial com-
panies were profit driven andmore likely to cut corners in the pursuit of profits
over consumer safety. In contrast there was high trust in public bodies such as
the blood transfusion services and the NHS.
However this discussion on commercialisation was tempered in part by a
realisation that commercial companies are necessary in the development of
healthcare technologies, and that we already rely heavily on such companies to
innovate new pharmaceutical products and devices.
‘Pretty much all the drugs that have been developed have been developed by industry
for commercial gain but it benefited everyone hugely and probably half of these drugs
wouldn’t be here if it wasn’t for the commercial drive to do it. It’s all very well saying
it’s for public good and it should be for everyone but that’s not how things get developed,
or very expensive things get developed. It seems that the blood thing is coming from
this position that we’re in now where there’s this ethos of giving and it’s available to
everyone and it’s not for profit. There’s a sort of a tension.’ (Focus group)
‘Can I suggest, we’re talking from a slightly naïve point. We in the UK have this
perception of everything being free on the NHS, albeit we’re paying for it through
other methods, this is not something that is going to be exclusively done in the UK,
this is going to be taken up in America or wherever else, either now or at some point
in the future. So whether it’s developed in the UK and then licensed out or whether
America says we can do this as well. Who’s going to pay for that? Is it going to be
private companies who see the long-term game plan that would make billions out of
it, and without that private money going in, is it ever actually to get to the point of
making it to production? I’ve no idea how much the Wellcome Trust has, and if
they’re the only body who are involved in this, but sooner or later surely they’re going
to say, wait a minute we’ve spent it all, and this is going to run for 20 years until it
comes to production.’ (Focus group)
There was a lack of awareness amongst many of the participants about the
true cost of many healthcare practices in the UK, including blood donation,
which the participant is referring to here, and which will be discussed further
below.
157Journal of Medical Law and Ethics 2015-3
BIODIVERSITY AND PERCEPTIONS OF RISK
Theme 2: Lack of biodiversity as increased risk
People also compared cultured blood to GM crops as a view that a lack of
biodiversity was somehow riskier. In some unrecorded mini-focus groups the
participants referred to the problems of having all the eggs in one basket (what
would happen if something went wrong), or of a general (but unspecified) un-
ease about ‘everything being the same’.
‘I meant in terms of the practicalities, would it not be better to have a cocktail of
individuals come together for the red blood cells, for your stock? But I don’t know
whether that is a technical issue. Just thinking from a general biological perspective,
having your feedstock based on a single individual can run into problems, and often
unexpected problems. Although I appreciate that with red blood cells you’ve not got
the genetic issue. I don’t know enough about the technicalities but just from a general
biological perspective I don’t know how wise it would be to base it all on a single indi-
vidual, but I’m sure your guys know what they’re doing.’ (Interview)
Despite the fact that there might not be a biological basis for a lack of bio-
diversity to result in increased risk, it was recognised as a legitimate risk factor
that many people might identify. This interviewee believed that this stemmed
from the fear of the unknown about cultured blood products, although in this
case it was compared to irradiated foods rather than GM crops.
‘That sense of perception that “I don’t know how all this stuff works, but natural
to have reactions like thinking this may be passed on”. Similar to the reactions to ir-
radiated food etc. In terms of scientific rationale it is completely wrong, but it terms
of how people frame issues then that is the way that they think.’ (Interview)
Again this was balanced by the view that a lot of the reactions we have to
GM crops have been picked up frommedia stories, and do not necessarily reflect
reality.
‘You’d think some of the reception in the greater world out there would depend
on how the media present this, in focus groups like this we can talk calmly and ratio-
nally about it but how would the media present it to the greater population? We’ve
seen the GM foods, Frankenfoods and all this kind of thing, how would that be
presented? That would be a concern as to how the scientific world presented it via the
media, what the media actually took.’ (Focus group)
Theme 3: Cultured blood in a social context
The final theme was that of biodiversity affecting how we view cultured
blood in a social context. Currently blood in the UK is given bymany thousands
of anonymous donors and has a strong sense of ‘gift giving’. However as partic-
ipants raised, this may change if all the blood being produced is coming from
one or a small number of stem cell lines.
Journal of Medical Law and Ethics 2015-3158
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‘But if things, if everything can be bought or sold, if the concept of gift is no longer
something that is valued in society, people in America sell their blood, apparently all
along the border withMexico there’s a whole lot of blood clinics because they’re getting
the blood from the poorMexicans. If this concept of solidarity, a gift is no longer valued
or even made possible then I think society as a whole will be weakened.’ (Interview)
In this quote the interviewee appears to be relating a change in the social
context of blood donation to the increased commercialisation and profit making
around blood. Whereas in the quote below the participants are reflecting on
the perceived lack of biodiversity, with all the blood coming from a single source
rather than the many altruistic donors.
‘F1: I guess there’s also the point that there might be six or ten nationwide sources
of this blood, six or ten people walking around in the UK whose blood is now in the
veins of a million people, and that’s not how it is at the moment [?] people, whether
that would bother people.
F2: I suppose it’s removing diversity, isn’t it …
F1: People would have a problem with that, the way that people have problems
with perceiving organs more than they do giving blood for some reason carrying part
of that person around with them, does it make a difference if everyone is carrying a
part of the same person?’ (Focus group)
Although red blood cells only last around 120 days in the body there is still
a perception that one is receiving part of another person, although, as is high-
lighted in the quote, perhaps less than through an organ transplant.
Discussion
Focus group and interview participants discussed biodiversity
in the context of cultured blood in three ways. The first was a comparison of
cultured blood to GM crops, the second was a perceived increased risk in cul-
tured blood, and the third theme was a supposed social difference between
cultured and donated blood.
In the first theme participants compared cultured blood to GM crops as a
commercialisation of something which is regarded as intrinsically ‘free’. It was
argued that this commercialisationmight lead to restrictions on access to blood.
A socioeconomic concern about GM crops has been the terminator technology
put in place by some GM crop companies, which renders GM seeds sterile. If
farmers wish to continue with the GM crops they must return to the company
each year to buy seeds, which some see as creating a monopoly by the GM seed
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companies.25 Similarly participants highlighted the potential risk of a cultured
blood company putting a high price on blood which wouldmake it unaffordable
for the NHS or for individuals. In comparing cultured blood to GM crops our
participants were reacting to what they saw as the restriction of something
natural and ‘free’, a monopoly on something which is currently given as an al-
truistic gift.26
Such discussions speak to a wider question of commercialisation vs. open
source science.27 On one hand technologies such as GM crops, or cultured
blood, are seen to commercialise something which is regarded as naturally
available. On the other hand a lack of monetary incentive could dissuade com-
mercial involvement in future research.28 In the UK the true cost of blood pro-
duction remains relatively hidden within the ‘black-box’ of the NHS. But the
large amounts of processing and testing carried out means that blood is essen-
tially already a commercialised product, with a biovalue that is becoming in-
creasingly recognised.29, 30 Indeed some participants attempted to raise the issue
that we rely on commercialisation all the time for pharmaceutical developments,
but that we simply are not aware of this because everything is done through
the umbrella of the NHS. They were also aware that the NHS is unlikely to
produce all the blood necessary for the entire world, meaning that other coun-
tries may be able to set prices for cultured blood which are outside the control
of the UK developers.
Cultured red blood cells were perceived by participants to bemore risky due
to their perceived lack of biodiversity, compared to the current donation system
which acquires blood from many individual donors. Increased risk was seen
due to the possibility that, with a single stem cell line, if problems were found
in this blood then thousands of people would be affected. Participants felt that
to produce only one blood source was akin to ‘putting all the eggs in one basket’,
with no knowledge of whatmight happen in years to come or whether that stem
cell line would turn out to have some vital flaw. Conversely one of the aims of
cultured red blood cells is to reduce the risk disease transmission due to the
current method of obtaining blood from many different donors. The transfer
of hepatitis from donor to recipient was an ongoing problem for many years,
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howevermorewidely publicisedwas theHIV contamination of plasma products,
which was first recognised in the early 1980s and affected many haemophi-
liacs.31, 32 The authorities were slow to inform patients or withdraw infected
batches, which Starr33 attributes to the reverence given to blood and its symbolic
nature as a social gift, rather than a pharmaceutical product. Previous work,
however, has shown that despite infection risks donated human blood is still
preferred over any other source,34, 35 including bovine derived, and synthetic
blood. This work, however, did not take into account the prospect of stem cell
derived blood, which is still human blood, just produced in a laboratory.
Finally the participants discussed biodiversity as it affects the social element
of blood donation. This theme was heavily intertwined with the perception of
risk from a lack of biodiversity, but focused more on the social connections
between blood donors and recipients. Red blood cells have no nucleus or nuclear
DNA, yet one group specifically said that this did not change theirminds because
there could be ‘something else’ (which was undefined) which meant that the
blood given by each different individual was unique to them. There was inherent
unease about all the blood in theUK potentially coming from a single individual
(even if that ‘individual’ is a stem cell line). For so many years the public in the
UK have been used to blood coming from multiple donors, an act of altruism
which has led to themany comparisons between blood donation and gift giving.
There is still a view that some of the individual is transferred in some way
through donation, be that a donation of blood or organs.36With blood donation
in the UK currently using altruistic donors there is an element of ‘not knowing’
where this blood comes from and who the original donor is. In contrast this
cultured blood is a known entity, as every recipient will be getting red blood
cells grown from a single (or a small number) of donor lines.
Blood appears to fit a special criteria, especially in the UK, given the attach-
ment to the transfusion services and the gift relationship around blood. Many
participants seemed unable to articulate exactly what is was about the lack of
diversity in red blood cells that they disliked, almost in themanner of the ‘yuck’
factor.37 Participants also did not compare the blood to any other technologies,
although this may have been for two reasons, one that they were not prompted
D. Starr, Blood: an Epic History of Medicine and Commerce (Little, Brown and Company, 1999),
262.
31
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down this route by the focus group/interview facilitator, and the other that we
tend to compare new technologies with those we are used to or estimate risks
based on those technologies which are more prevalent in the media.38 It is
perhaps unsurprising that participants were not so well acquainted with other
comparable technologies such as synthesised insulin or Factor VIII, but were
more aware of higher profile technologies such as blood transfusion and GM
crops. This would be a limitation of this study, as it is with all qualitative studies,
that the influence of the questions asked and the particular setting of the group
or interview can have such a strong influence on the outcomes. However, given
that so many of the groups and interviews brought up the issue of GM crops
without prompting gives some weight to the idea that this topic was foremost
in participants’ minds as a comparator technology.
Younger respondents did not appear to have such an attachment to the
donation system as the older ones did, and therefore saw the cultured red blood
cells as clean, more sci-fi and scientific. This seems to be linked to the general
lack of contact with the blood transfusion services compared to older participants,
many of whom had either received a transfusion or had been donors for many
years. Indeed this comparesmore with the reaction of the scientists themselves,
who see less risk in the standardisation of blood, as it will come from a single
‘known’ source rather thanmany ‘unknown’ donors.With risk perception based
on the perceived ‘trustworthiness’ of companies39 it will be interesting to see
how this affects the risk perception of cultured blood, given that both this and
donated blood are associated with the SNBTS. One possibility is that perceptions
about the role of the blood transfusion services change as cultured blood be-
comes more prominent. Division in attitudes between younger and older
audiences is therefore an area which would benefit from further study. Carrying
out this research in the UK has highlighted issues that may have not been ex-
pressed elsewhere, because the expectation in the UK is that everybody, regard-
less of their income, receives all the health care that they require for no cost.
This has the additional result of making healthcare in the UK a black-box, with
many of us having no idea of the true cost of pharmaceuticals or medical pro-
cedures. It is worth noting that if this data had been collected in the US, for
example, then reactions to this issue of commercialisation may have been very
different. This comparison with other countries is an important area for further
study.
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Conclusion
In conclusion, the data show that participants compared cul-
tured red blood cells with GM crops and saw a lack of biodiversity as inherently
risky and a threat to the established social ties of donated blood. The commer-
cialisation of a natural product led to concerns about the monopoly of blood,
leaving it only available to those with the ability to afford it. Cultured blood was
seen asmore risky if all the blood came from one stem cell line, despite ongoing
problems with infection risks linked to the large number of altruistic donors
currently involved in the supply of red blood cells for transfusion. Finally the
altruistic and gift-like nature of blood was seen as being replaced by the homog-
enous donor blood, and in doing so some of the social interaction of blood
transfusion was being removed. Although only a small number of our partici-
pants were young adults (18-25 years) they appeared to have a weaker attachment
to the transfusion services and viewed the cultured blood as cleaner and more
scientific. This was therefore a suggestion for further work, alongside a compar-
ison of the attitudes to cultured blood in countries which do not operate under
a system of national health provision.
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